Vincerx Pharma Inc
NASDAQ:VINC
Intrinsic Value
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of VINC.
Vincerx Pharma Inc's market capitalization is 19.3m USD.
VINC stock price is 0.9 USD.
VINC.
VINC. Open DCF Valuation
VINC. Open Relative Valuation
VINC has upside potential of 920% compared to the average analyst price target.
Open Wall St Estimates
VINC has negative Free Cash Flow for the last twelve months.
VINC has negative Operating Income for the last twelve months.
VINC has negative Net Income for the last twelve months.
VINC's ROE (Return on Equity) has significantly decreased in the last 3 years from -52% to -136%, and is approaching profitability.
VINC's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -59% to -1 284%, and is approaching profitability.
VINC's ROE (Return on Equity) for the past 12 months is negative and is equal to -136%.
VINC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 284%.
VINC's long-term assets (18m USD) exceed its long-term liabilties (7m USD).
VINC's short-term assets (15m USD) exceed its short-term liabilties (6m USD).
VINC has negative three-year average ROE (Return on Equity): -84%. The company is not efficient at transforming stockholders' equity into net income.
VINC has negative three-year average ROIC (Return on Invested Capital): -2 871%. The company is not efficient at using invested capital to generate operating income.
VINC's D/E (Debt to Equity) is very low and is equal to 0.
VINC's Altman Z-Score is very low and is equal to -18.02.
Fundamental Analysis
Vincerx Pharma Inc
Balance Sheet Decomposition
Vincerx Pharma Inc
| Current Assets | 14.7m |
| Cash & Short-Term Investments | 12.8m |
| Receivables | 1m |
| Other Current Assets | 907k |
| Non-Current Assets | 3.5m |
| PP&E | 2.3m |
| Other Non-Current Assets | 1.2m |
| Current Liabilities | 5.6m |
| Accounts Payable | 2.5m |
| Accrued Liabilities | 2.9m |
| Other Current Liabilities | 191k |
| Non-Current Liabilities | 1.4m |
| Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
Vincerx Pharma Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-42.6m
USD
|
|
Operating Income
|
-42.6m
USD
|
|
Other Expenses
|
2.5m
USD
|
|
Net Income
|
-40.2m
USD
|
Free Cash Flow Analysis
Vincerx Pharma Inc
What is Free Cash Flow?
VINC Profitability Score
Profitability Due Diligence
Vincerx Pharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Vincerx Pharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
VINC Solvency Score
Solvency Due Diligence
Vincerx Pharma Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Vincerx Pharma Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VINC Price Targets Summary
Vincerx Pharma Inc
According to Wall Street analysts, the average 1-year price target for
VINC
is 9.18 USD
with a low forecast of 8.08 USD and a high forecast of 10.5 USD.
Ownership
VINC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VINC Price
Vincerx Pharma Inc
| Average Annual Return | -8.27% |
| Standard Deviation of Annual Returns | 107.97% |
| Max Drawdown | -98% |
| Market Capitalization | 19.3m USD |
| Shares Outstanding | 21 345 000 |
| Percentage of Shares Shorted | 5.14% |
Company Profile
Vincerx Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2020-03-10. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.
You don't have any saved screeners yet
